Skip to search formSkip to main contentSkip to account menu

reviparin

Known as: reviparine 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

AnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-Weight

Narrower (4)

ClivarinClivarineLU 47311Reviparin sodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Acute generalized exanthematous pustulosis from dalteparin.
Highly Cited
2006
Highly Cited
2006
Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic Implications
The currently available brand-name low-molecular-weight heparins (LMWHs) in the United States include dalteparin (Pfizer… 
2004
2004
Severe anaphylactic reaction in a haemodialysis patient after administration of reviparin.
The anticoagulation with LMWH in haemodialysis patients can nause serious anaphylactic reactions. 
2001
2001
Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin).
BACKGROUND Low-molecular-weight heparin (LMWH) has been shown to prolong survival of rat cardiac allografts independently from… 
2000
2000
Interaction between the LMWH reviparin and aspirin in healthy volunteers.
AIMS To investigate potential interactions between reviparin and acetylsalicylic acid (ASA 300 mg o.d. from day 1-5). METHODS… 
2000
2000
Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury.
Highly Cited
1999
Highly Cited
1999
Local drug delivery: Impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall
Injection parameters for local drug delivery are frequently determined by studies with marker substances. However, the… 
1998
1998
Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: Preliminary results of an ongoing study
Purpose: To examine the efficacy of the low-molecular-weight heparin, reviparin, for prevention of femoropopliteal stent… 
1996
1996
Preclinical studies on a low molecular weight heparin.
1993
1993
First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) remains a major problem limiting the clinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)